TECH - Bio-Techne Corporation
| Previous Close | 160.32 |
| Open | 159.72 |
| Bid | 155.20 x 1200 |
| Ask | 199,999.98 x 800 |
| Day's Range | 158.84 - 164.15 |
| 52 Week Range | 128.06 - 206.04 |
| Volume | 229,902 |
| Avg. Volume | 260,941 |
| Market Cap | 6.116B |
| Beta (3Y Monthly) | 1.39 |
| PE Ratio (TTM) | 48.65 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.28 (0.83%) |
| Ex-Dividend Date | 2018-11-08 |
| 1y Target Est | N/A |
- PR Newswire•2 days ago
Bio-Techne To Host Conference Call On February 5, 2019, To Announce Second Quarter 2019 Financial Results
MINNEAPOLIS , Jan. 16, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, February 5, 2019 , at 8:00 a.m. CST to review second ...
- PR Newswire•29 days ago
Bio-Techne To Present At The 37th Annual J.P. Morgan Healthcare Conference
MINNEAPOLIS , Dec. 20, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer will present at the 37 th Annual J.P. Morgan ...
- PR Newswire•last month
Bio-Techne Releases GMP ROCK Inhibitor and CHIR 99021 for Stem Cell Therapy
MINNEAPOLIS , Dec. 4, 2018 /PRNewswire/ -- Bio-Techne has further added to its cell therapy portfolio by expanding the range of Tocris Bioscience-branded cGMP small molecules to include the commonly used ...
- PR Newswire•2 months ago
Bio-Techne To Present At The Citi 2018 Global Healthcare Conference
MINNEAPOLIS , Nov. 20, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Dave Eansor , President Protein Sciences will present at the Citi 2018 Global Healthcare Conference ...
- GlobeNewswire•3 months ago
Report: Exploring Fundamental Drivers Behind Equity Lifestyle Properties, AvalonBay Communities, Kadant, Mastercard, Bio-Techne, and Erie Indemnity — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•3 months ago
Bio-Techne Declares Dividend
MINNEAPOLIS , Oct. 30, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September ...
- PR Newswire•3 months ago
Bio-Techne Releases First Quarter Fiscal 2019 Results
MINNEAPOLIS , Oct. 30, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2018 . First Quarter FY2019 Snapshot First ...
- PR Newswire•3 months ago
Bio-Techne To Present At The 2018 Stephens NY Investment Conference
MINNEAPOLIS , Oct. 26, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 2018 Stephens NY Investment ...
- PR Newswire•3 months ago
Bio-Techne Signs Strategic Cooperation Agreement with Micropoint Bioscience
MINNEAPOLIS, Oct. 12, 2018 /PRNewswire/ -- Bio-Techne has entered into a strategic cooperation agreement with Micropoint Bioscience of Shenzhen, China. Chuck Kummeth, President and CEO of Bio-Techne, Yan Pingyi, Chairman of Micropoint Bioscience, and Wang Bin, Executive Vice President, Shenzhen Association of Medical Devices, all attended the meeting and signing ceremony. Micropoint Bioscience is a high-tech, newly-listed enterprise in China that has developed a microfluidic diagnostic chip for point-of-care (POC) testing.
- PR Newswire•3 months ago
Bio-Techne To Host Conference Call On October 30, 2018 To Announce First Quarter 2019 Financial Results
MINNEAPOLIS , Oct. 11, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, October 30, 2018 at 8:00 a.m. CDT to review first ...
- PR Newswire•4 months ago
Bio-Techne Scientist Presented with the CASSS CE Pharm Award
MINNEAPOLIS , Oct. 2, 2018 /PRNewswire/ -- Bio-Techne is proud to announce that one of its Principal Scientists, Jiaqi Wu , Ph.D., was presented with the CE Pharm Award at this year's CE Pharm meeting ...
- PR Newswire•4 months ago
Bio-Techne Announces Cell and Gene Therapy Initiative
MINNEAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Bio-Techne, a global leader of research and manufacturing-grade reagents, has announced a corporate initiative to advance cell and gene therapy research and ex vivo cell processing. Through strategic acquisitions and internal scientific innovation, Bio-Techne has become uniquely positioned to provide a comprehensive, innovative, and flexible set of reagents and instrumentation across the cell and gene therapy workflow. Bio-Techne's solutions for the cell therapy workflow span its portfolio, including GMP-grade cytokines and growth factors, high-quality antibodies for flow cytometry and immunocytochemical characterization, gold-standard immunoassays and next-generation automated immunoassay platforms, DNA and RNA in situ hybridization (ISH) assays, GMP-grade small molecules, and more.
- PR Newswire•4 months ago
Bio-Techne Supports International Antibody Validation Meetings
MINNEAPOLIS, Sept. 19, 2018 /PRNewswire/ -- Bio-Techne is proud to be sharing its 30+ years of industry leading expertise in antibody development and validation from its R&D Systems and Novus Biologicals brands at the 3rd International Antibody Validation Meeting on September 20-21, 2018. Leading researchers from academia, the biopharma industry, and antibody developers will gather to discuss best practices in research antibody validation with the goal of improving validation standards and enhancing research reproducibility. Birte Aggeler, Ph.D., Director of Antibody Development and Flow Cytometry at Bio-Techne, will present results from Bio-Techne's newest approaches to antibody validation, including the company's initiative to use CRISPR gene editing technology to validate antibodies in knockout (KO) cell lines.
- PR Newswire•4 months ago
Bio-Techne Announces Publication of Data Demonstrating Additional Clinical Validation of its EPI Test in European Urology Journal
MINNEAPOLIS , Sept. 18, 2018 /PRNewswire/ -- Bio-Techne today announced the online publication of its second prospective US clinical validation study of the Exosome Diagnostics-branded ExoDx® Prostate(IntelliScore) ...
- PR Newswire•4 months ago
Bio-Techne Fills a Need for Simple Tools to Study Glycobiology
MINNEAPOLIS, Sept. 6, 2018 /PRNewswire/ -- Bio-Techne researchers publish papers that promise to open the field of glycobiology to the masses. This modification of proteins is called glycosylation. Because glycans have been tied to many pathologies, ranging from cancer to neurodegenerative disease, it is important to better understand their structures and functions.
- PR Newswire•4 months ago
Bio-Techne To Present At The Morgan Stanley 16th Annual Global Healthcare Conference
MINNEAPOLIS , Sept. 5, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Morgan Stanley 16 th Annual ...
- PR Newswire•5 months ago
Bio-Techne To Present At The Baird 2018 Global Healthcare Conference
MINNEAPOLIS , Aug. 28, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Baird 2018 Global Healthcare ...
- PR Newswire•5 months ago
Bio-Techne Introduces GMP Small Molecules for Stem Cell Therapy Development
MINNEAPOLIS, Aug. 8, 2018 /PRNewswire/ -- Bio-Techne has introduced a new range of Tocris Bioscience-branded stem cell research compounds produced to cGMP standards, which are suitable for use as ancillary materials in the development of stem cell therapies. Bio-Techne has a highly-qualified team who have full control over the cGMP process, meaning we can ensure: a quality assured manufacturing system, guaranteed batch-to-batch consistency, traceability from starting material to final product, and consistency of supply. GMP compounds are synthesized in accordance with relevant sections of ICH Q7 guidelines, and are classified as tier 2 risk in the USP guidelines.
- ACCESSWIRE•5 months ago
Bio-Techne Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Bio-Techne Corporation (NASDAQ: TECH ) will be discussing their earnings results in their Q4 Earnings Call to be held on August 7, 2018 at 9:00:00 AM Eastern ...
- PR Newswire•5 months ago
Bio-Techne Declares Dividend
MINNEAPOLIS , Aug. 7, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2018 ...
- PR Newswire•5 months ago
Bio-Techne Releases Fourth Quarter Fiscal 2018 Results
MINNEAPOLIS , Aug. 7, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ended June 30, 2018 . Fourth Quarter and Full Year FY2018 Snapshot ...
- PR Newswire•6 months ago
Bio-Techne Announces 2018 Investor Day And Webcast
MINNEAPOLIS , Aug. 2, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host its 2018 Investor Day on Friday, September 7, 2018 , starting at 9:00 a.m. EDT ...
- PR Newswire•6 months ago
Bio-Techne Corporation Completed Its Acquisition of Exosome Diagnostics, Inc.
MINNEAPOLIS, Aug.1, 2018 /PRNewswire/ -- Bio-Techne Corporation (TECH) today announced it has completed its acquisition of Exosome Diagnostics, Inc. The transaction consideration includes an upfront payment of $250 million plus an additional $325 million that can be maximally earned through calendar year 2022 upon reaching certain performance milestones. With this acquisition, Minneapolis-based Bio-Techne now has a world-wide workforce in excess of 2,100 and has expanded its global reach with subsidiaries in every major geographic market. This acquisition continues to build on Bio-Techne's strategy to expand its market reach beyond its legacy research market into the liquid biopsy diagnostic arena with the introduction of Exosome Diagnostics' non-invasive prostate molecular test (EPI) to help physicians better serve their patients when considering the need for a prostate biopsy.
- PR Newswire•6 months ago
Bio-Techne Introduces New Member of the Simple Western™ Family, with IR/NIR Detection Capabilities
MINNEAPOLIS , July 24, 2018 /PRNewswire/ -- Bio-Techne again disrupts protein analysis technology with the introduction of the newest member of their ProteinSimple-branded Simple Western family, Jess. ...